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A B S T R A C T
Malignant hepatic epithelioid hemangioendothelioma (HEH) is a rare malignant tumor of vascular origin with un-
known aetiology and a variable natural course. At the time of diagnosis, most patients present with multifocal tumours
lesions that involve both liver lobes. From the therapeutic aspect, liver resection (LRx), liver transplantation (LTx), che-
motherapy, radiotherapy, and/or immunotherapy have been used in the treatment of patients with HEH. However, be-
cause of the rarity of this tumor and its unpredictable natural history, it is impossible to assess the effectiveness of these
respective therapies. In this report, our objective was to present clinical aspects, diagnostic options, therapeutic modali-
ties, and the clinical outcome of single patient with LTx because of this rare tumor.
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Introduction
Malignant hepatic epithelioid hemangioendothelioma
(HEH) is a rare malignant tumor of vascular origin with
unknown aetiology and a variable natural course. The
term epithelioid hemangioendothelioma was defined as a
distinct entity first by Weiss and Enzinger in 1982 as a
soft tissue vascular tumor of endothelial origin with a
clinical course between benign haemangioma and angio-
sarcoma1. HEH most commonly affects adult females. At
the time of diagnosis, most patients present with multi-
focal tumours lesions that involve both liver lobes. Most
common sites of extra hepatic involvement are lungs,
peritoneum, lymph nodes, and bones1.
Based on current knowledge, no definitive etiology
has been confirmed as a causative factor for HEH. Some
possible risk factors of HEH include oral contraceptives,
vinyl chloride, asbestos, major trauma to the liver, viral
hepatitis, primary biliary cirrhosis, gold compounds and
alcohol consumption2. HEH, in contrast to many other
types of primary liver tumor, does not typically arise in
a background of chronic liver disease, as described pre-
viously2.
Clinical manifestations of HEH are uncommon and
non-specific. Makhlouf et al. reported findings in a series
of 137 patients with this tumor3. At the time of diagnosis,
25% of reported patients were asymptomatic. Among
symptomatic patients, the most common clinical mani-
festations were right upper quadrant pain (48.6%), he-
patomegaly (20.4%), and weight loss (15.6%). Weakness,
anorexia, epigastric mass, ascites, nausea/emesis, jaun-
dice, and fatigue were the next most common presenting
manifestations. Eighty-seven percent of patients pre-
sented with a multifocal tumor that involved both liver
lobes, whereas only 13% of the patients had a unifocal tu-
mor. The right lobe was affected more than the left lobe
in both multifocal and unifocal presentations. Extra he-
patic involvement at the time of diagnosis was observed
only in 36.6% of patients. Out of other reported sites
spleen is involved in 3.2% of cases. Eighty percent of pa-
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tients had abnormal laboratory findings. Most tumor
markers (e.g., alpha-fetoprotein, carcinoembryonic anti-
gen, and CA 19-9) were in the normal range and, in the
current context, were suitable only for ruling out other
primary or metastatic liver tumors.
On ultrasonography, most frequently (66%), the le-
sions are hypoechoic relative to the adjacent hepatic
parenchyma4. The other patterns of echogenicity include
heterogeneous (22.5%), hyperechoic (6.2%), and isoechoic
with hypoechoic rim (5%) appearance. On computed to-
mography (CT) scans most often low-density abnormal
pattern is reported (98% of patients). Normal CT scans
are reported in 1.4% of patients. HEH usually is hypo-
intense on T1-weighted images and hyperintense on
T2-weighted images by magnetic resonance images. The
target appearance of the lesions may be caused by the
presence of a central sclerotic zone and a peripheral re-
gion of cellular proliferation. Central low-signal areas
may correspond to haemorrhage, coagulation necrosis,
and calcification; whereas peripheral high signal inten-
sity corresponds to oedematous connective tissue and vi-
able tumor. Angiographic examination of the liver is per-
formed only in selected patients and reveals only moderate
vascularization. In literature review findings were comple-
tely heterogeneous, ranging from hypo- to hyperperfusion2.
Generally, in the nodular form, a specific diagnosis is
impossible without performing a fine needle aspiration
cytology or biopsy because the radiology findings are sim-
ilar to those in some hepatic metastases. Tumor is char-
acterized by an epithelioid or histiocytoid morphology
and a growth pattern with evidence of endothelial histo-
genesis5. Cells show prominent mucin negative cytoplas-
matic vacuoles. Red blood cells may be present within
some of these vacuoles (reminiscent of primitive vascular
channels). Its vascular nature is confirmed by positive
staining for factor VIII-related antigen and/or other en-
dothelial cell markers (CD31, CD34) in addition to the
ultrastructural characteristics of well developed basal
lamina, pinocytotic vesicles, and, more specifically, Weibel-
-Palade bodies. Some cases show positivity to smooth
muscle actin, vimentin and cytokeratin. Epithelial mem-
brane antigen (EMA) and S-100 staining patterns are
negative. Immunohistochemical identification of factor
VIII related antigen is helpful in differentiating between
metastatic carcinoma and primary epithelial liver tu-
mors5. Generally there is low mitotic activity and mild to
moderate pleomorphism. Cases with tumor cells display-
ing cytological atypia, increased mitotic activity and ne-
crosis and high cellularity could be related with worsen
outcome. But clinical course of this tumor is quite vari-
able and cytological analysis could not be used to predict
disease outcome.
Clinical course of HEH is variable, ranging from a fa-
vourable disease with prolonged survival, even without
therapy, to a rapidly progressive disease with a grave out-
come. Liver resection therapy (LRx) is the treatment of
choice in patients with resectable HEH. However, in pa-
tients with multifocal liver tumor the most common
management procedure is liver transplantation (LTx). In
addition, LTx is an acceptable option for patients who
have HEH with extrahepatic manifestation. The 1-year
and 5-year patient survival rates are 96% and 54.5%, re-
spectively, after LTx; 39.3% and 4.5%, respectively, after
no treatment, 73.3% and 30%, respectively, after chemo-
therapy or radiotherapy; and 100% and 75%, respec-
tively, after (LRx)2.
Case Report
60 year old female patient with psoriatic arthritis was
treated for six years with metotrexate (cumulative dose
460 mg) and gold compounds. Eight years before definite
diagnosis patient presented with signs of liver damage
(pathological aminotraspherases) and multiple hipoeho-
genic lesions on liver ultrasound. All psoritatic arthritis
therapy thereafter was stopped. Laboratory oncogenic
markers (AFP, CEA, CA 19-9, CA 125, CA 15-3) were all
in normal ranges. By repeated biopsies malignant alter-
ation was not confirmed and diagnosis of tumor lesions
was undefined. For years ago patient developed signs of
ascites. Bioptic samples of tumor uninvolved liver tissue
revealed cirrhosis. Because tests to all other etiological
factors were negative (alcohol consumption, viral serol-
ogy, immunological tests, and copper in bioptic sample)
etiology was related with postnecrotic changes. Since
that time liver ultrasound and multislice CT displayed
slow progression in size of confluent hipoechogenic/hypo-
dense tumor lesions in both liver lobes (3 cm maximal di-
ameter) and appearance of one new lesion (4 cm in diam-
eter) in spleen. Some tumors displayed signs of central
necrosis. Angiography revealed no signs of pathological
arterial vascularistion.
In our centre patient appeared one year ago with
symptoms of upper quadrant pain, nausea, weight loss,
weakness, ascites, and jaundice. Laboratory findings re-
vealed elevated level of aminotranspherases, alkaline
phosphatase and gamaglutiltranspherase (within twice
of upper normal level), hiperbilirubinaemia (5 fold hi-
gher than upper normal limit), low protrombin time
(64%), normocytic normochromic anemia (Hgb 90 MCV
96.4 MCHC 340), and signs of renal failure (kreatinin
klirens 33 mL/min). Ultrasound examination confirmed
multiple tumor lesions in both liver lobes and one lesion
in spleen. Ultrasound guided fine needle aspiration of tu-
mor mass in left liver lobe and spleen was performed. Cy-
tological examination was suggestive of malignant epi-
theloid hemangiendothelioma (Figure 1). Tumor cells
were staining positive to anti CD31 (Figure 2), anti CD
34 (Figure 3), vimentin and factor VIII related antigen.
Multiple tumor lesions in cirrhotic liver were consid-
ered nonresectible. Since multiphocal malignant heman-
giendothelioma is considered in literature for liver trans-
plantaton it was proposed to patient. According to rules
of Eurotransplant organization patient was reconsidered
as non standard exception in indication for liver trans-
plantation.
Standard orthotropic liver transplantation with total
spleenectomy was performed in December 2008. Explan-
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ted liver represented multiple tumor lesions involving al-
most entire liver with spleen metastasis. Patient is trea-
ted with regular immunosuppressive therapy consisted
of combination with tacrolims and mycophenolic acid.
First month postoperative treatment was complicated
with E. coli sepsis and progression of renal insufficiency.
Both were successfully treated with standard procedures
including antibiotics and correction of tacrolimus dose.
Forth month after transplantation patient developed
acute diarrhoea with signs of toxic megacolon and again
with progression of renal insufficiency. No signs of bacte-
rial or viral pathogens were detected in stool and possible
explanation for toxic megacolon was related with toxic
levels of calcineurin inhibitor (tacrolimus). Total cole-
ctomy was performed and tacrolimus stopped in therapy.
After therapy correction patient went better and was re-
leased form hospital.
So far (8 months after LTx) patient has been treated
with combination of mycophenolic acid and corticoste-
roid immunosuppressant and there is no sign of recur-
rence of primary disease.
Discussion and Conclusion
HHE is rare vascular tumor of liver. Positive imaging
findings in addition to certain features, such as occur-
rence in younger adults, the presence of numerous intra-
hepatic tumors with a good clinical condition, slow course
of the disease, and the presence of intratumoral cal-
cifications, are suggestive for HEH6,7. But the definitive
diagnosis of this rare liver tumor requires a cytological or
histopathologic analysis. The diagnosis mostly is con-
firmed by immunohistochemical evidence of endothelial
differentiation, as demonstrated by the presence of fac-
tor VIII-related antigen (in nearly all patients), the pres-
ence of CD34 (94%), and CD31 (86%). Often, a laparo-
scopic wedge or core biopsy is sufficient to encompass the
architectural features of HEH, such as the intravascular
characteristics. In presented case definite diagnosis was
confirmed by fine needle aspiration cytology.
Variable patterns of the tumor may mimic other le-
sions5. As in this case, in the literature rewiev, approxi-
mately 60% to 80% of patients with HEH initially were
misdiagnosed2. The most common misdiagnoses are cho-
langiocarcinoma, angiosarcoma, hepatocellular carcino-
ma, metastatic carcinoma, and sclerosing hemangioma.
Mixed hamartoma, spindle cell neoplasm, inflammatory
pseudotumors, bile duct adenoma, cirrhosis, carcinoma
with chondromyxoid change, venooclusive disease, fibro-
lamellar carcinoma, postnecrotic fibrosis, and Budd-Chiari
syndrome were less common misdiagnoses.
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Fig. 1. Hepatic epitheloid hemangioendothelioma cells, fine needle
aspiration cytology smears (May-Grunwald-Giemsa staning).
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Fig. 2. Hepatic epitheloid hemangioendothelioma cells – positive
immunostaining to CD31 (LSAB).
Fig. 3. Hepatic epitheloid hemangioendothelioma cells – positive
immunostaining to CD34 (LSAB).
The management options for patients with HHE are
numerous. Theoretically, LRx is the first choice for cura-
tive treatment of HEH. Like in this case, in majority of
other patients, total resection is impossible because of
the multicentricity of the lesions or anatomic difficulties:
LTx is generally the most common treatment modality
(44.8)8. Improved clinical outcomes after LTx in the last
decade have provided further support in favour of under-
going LTx as curative treatment for HEH9. Significance
of chemotherapy and/or radiotherapy is difficult to as-
sess, mainly because of the lack of uniform treatment
modalities and prospectively collected data.
According to earlier experience tumor can spread to
other organs and presence of tumor cells displaying cyto-
logical atypia are not necessarily related with bad prog-
nosis. In this regard, the unpredictable natural course
and prognosis of HEH make it difficult to determine a
correlation between morphologic grading or clinical stag-
ing and outcome. The life expectancy of patients with
HEH potentially is good. Limited extrahepatic disease
should not be considered an absolute contraindication to
LTx10. Some authors have advocated LTx in the presence
of extrahepatic involvement based on the reports of a
5-year survival rate between 48% and 71% in patients
with HEH who had extrahepatic manifestations and un-
derwent LTx2,11. Most recurrences occurred beyond 2
years after transplantation12.
This case report represents first case of successfully
liver transplanted adult patient with multifocal HEH
with extrahepatic spleen involvement in Croatia. In ac-
cordance with earlier experience, despite multiflocal ap-
pearance of disease before LTx eight months after proce-
dure there are no signs of disease recurrence. In patients
with multifocal HHE and resectable extrahepatic disease
LTx seems rational option.
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EPITELOIDNI HAEMAGIOTELIOM U BOLESNIKA S TRANSPLANTACIJOM JETRE
S A @ E T A K
Maligni epiteloidni hemangioendoteliom jetre je rijetki maligni tumor porijeklom od stanica krvnih `ila s nepozna-
tom etiologijom i varijabilnim prirodnim tijekom. U vrijeme postavljanja dijagnoze ve}ina bolesnika prezentira se s
multifokalnim tumorskim promjenama koje zahva}aju oba re`nja jetre. U terapiji provode se postupci resekcije dijela
jetre, transplantacije jetre, kemoterapije, zra~enja i/ili imunomodulatorne terapije. Obzirom na rijetkost navedenog
tumora i nepredvidiv prirodni tijek bolesti nemogu}e je generalno procijeniti efektivnost navedenih terapija. U ovom
prikazu cilj je prikazati klini~ke aspekte, dijagnosti~ke mogu}nosti, terapijske modalitete i tijek bolesti kod bolesnice s
transplantiranom jetrom uslijed navedenog rijetkog tumora.
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